Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
AssigneeSeed Health, Inc.
InventorJoseph E. Kovarik
Life of this patent
Estimating the term…
Abstract
A method for reducing the likelihood of an individual developing colorectal cancer includes the use of a CRISPR system to selectively kill pathogenic bacteria, such as Klebsiella and E coli, within the individual. Preferrably, the growth of a beneficial bacteria, such as Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, and Streptococcus bacteria, is also enhanced. Reduction of certain virulence factors, such as colibactin, using a CRISPR system, as well the employment of immune checkpoint inhibitors, is effective in treating individuals with cancer and who suffer from a chronic infectious disease.
Claims19
A method for treating an individual who has colorectal cancer, comprising, using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas), selectively killing a pathogenic bacteria within the individual, said pathogenic bacteria selected from the group consisting of Klebsiella and E coli;
- and enhancing the growth of a beneficial bacteria in the individual selected from the group consisting of Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, and Streptococcus bacteria.
A method for treating an individual who has colorectal cancer, comprising, using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas), selectively killing a pathogenic bacteria within the individual, said pathogenic bacteria selected from the group consisting of Klebsiella and E. coli;
- and administering to the individual an immune checkpoint inhibitor that specifically binds to an immune checkpoint protein selected from the group consisting of CTLA4, PD-1, PD-L1, PD-L2, A2AR, B7-H3, B7-H4, BTLA, KIR, LAG3, TIM-3 and VISTA.
A method for treating an individual who has colorectal cancer, comprising, using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system from Prevotella and Francisella 1 (Cpf1), selectively killing a pathogenic bacteria within the individual, said pathogenic bacteria selected from the group consisting of Klebsiella and E. coli;
- and wherein the CRISPR-Cpf1 system is used to facilitate RNA-guided site-specific DNA cleavage to kill the pathogenic bacteria;
- wherein using the CRISPR-Cpf1 system said pathogenic bacteria are killed while sparing other commensal bacteria;
- and wherein the CRISPR-Cpf1 system is delivered to the pathogenic bacteria using a bacteriophage.
Dependencies are inferred from the claim text.